JP2022088646A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022088646A5 JP2022088646A5 JP2022063361A JP2022063361A JP2022088646A5 JP 2022088646 A5 JP2022088646 A5 JP 2022088646A5 JP 2022063361 A JP2022063361 A JP 2022063361A JP 2022063361 A JP2022063361 A JP 2022063361A JP 2022088646 A5 JP2022088646 A5 JP 2022088646A5
- Authority
- JP
- Japan
- Prior art keywords
- gel composition
- stable gel
- micronized
- stable
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 39
- 150000003839 salts Chemical class 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 7
- 239000000227 bioadhesive Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 4
- 229920002678 cellulose Polymers 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 210000003491 skin Anatomy 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 229920013820 alkyl cellulose Polymers 0.000 claims 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 claims 2
- 229960000766 danazol Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001804 emulsifying effect Effects 0.000 claims 2
- 229960005309 estradiol Drugs 0.000 claims 2
- 229930182833 estradiol Natural products 0.000 claims 2
- 230000003054 hormonal effect Effects 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 229950005134 polycarbophil Drugs 0.000 claims 2
- 229960003604 testosterone Drugs 0.000 claims 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims 1
- 206010013786 Dry skin Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 230000037336 dry skin Effects 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- -1 propylene glycol isostearates Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 210000000434 stratum corneum Anatomy 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024062228A JP2024083507A (ja) | 2016-01-07 | 2024-04-08 | 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275955P | 2016-01-07 | 2016-01-07 | |
| US62/275,955 | 2016-01-07 | ||
| US201662371670P | 2016-08-05 | 2016-08-05 | |
| US62/371,670 | 2016-08-05 | ||
| PCT/US2017/012564 WO2017120492A1 (en) | 2016-01-07 | 2017-01-06 | Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof |
| JP2018554642A JP7055754B2 (ja) | 2016-01-07 | 2017-01-06 | 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554642A Division JP7055754B2 (ja) | 2016-01-07 | 2017-01-06 | 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062228A Division JP2024083507A (ja) | 2016-01-07 | 2024-04-08 | 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022088646A JP2022088646A (ja) | 2022-06-14 |
| JP2022088646A5 true JP2022088646A5 (enExample) | 2023-02-17 |
Family
ID=58463817
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554642A Active JP7055754B2 (ja) | 2016-01-07 | 2017-01-06 | 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 |
| JP2022063361A Pending JP2022088646A (ja) | 2016-01-07 | 2022-04-06 | 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 |
| JP2024062228A Pending JP2024083507A (ja) | 2016-01-07 | 2024-04-08 | 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554642A Active JP7055754B2 (ja) | 2016-01-07 | 2017-01-06 | 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062228A Pending JP2024083507A (ja) | 2016-01-07 | 2024-04-08 | 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20170196896A1 (enExample) |
| EP (2) | EP3399963B1 (enExample) |
| JP (3) | JP7055754B2 (enExample) |
| KR (1) | KR20180117103A (enExample) |
| CN (1) | CN108712901A (enExample) |
| AU (2) | AU2017206048B2 (enExample) |
| CA (1) | CA3010829A1 (enExample) |
| ES (1) | ES2949053T3 (enExample) |
| GB (1) | GB2551598B (enExample) |
| IL (2) | IL300437A (enExample) |
| MX (2) | MX393613B (enExample) |
| WO (1) | WO2017120492A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018091473A1 (en) | 2016-11-15 | 2018-05-24 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| MX2019015927A (es) * | 2017-06-22 | 2020-08-06 | Viramal Ltd | Composiciones para administración de fármacos y métodos de uso de las mismas. |
| WO2019093780A1 (ko) * | 2017-11-10 | 2019-05-16 | (주)아모레퍼시픽 | 바이겔 타입의 화장료 조성물 |
| CN108635330B (zh) * | 2018-04-17 | 2021-11-30 | 上海普特生物科技有限公司 | 一种长效缓释黄体酮凝胶剂组合物 |
| GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| SMT202400056T1 (it) | 2018-07-30 | 2024-03-13 | Biothea Pharma Inc | Sale cristallino di malonato di epinefrina |
| EP3870150A1 (en) * | 2018-10-26 | 2021-09-01 | Viramal Limited | Mucoadhesive gel composition |
| ES2948955T3 (es) * | 2018-11-30 | 2023-09-22 | Viramal Ltd | Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante |
| EP3922235A1 (en) * | 2020-06-11 | 2021-12-15 | Viramal Limited | A hydroalcoholic gel and a method of manufacturing said gel |
| JP2024505970A (ja) * | 2021-02-02 | 2024-02-08 | デュポン・ニュートリション・ユーエスエイ，インコーポレイテッド | エチルセルロースを含有する水性ゲル組成物 |
| CN112970804A (zh) * | 2021-03-29 | 2021-06-18 | 陕西农产品加工技术研究院 | 一种基于甘油二酯油凝胶的枸杞面包及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US618323A (en) | 1899-01-24 | Berndt e | ||
| FR2739559B1 (fr) * | 1995-10-05 | 1997-11-28 | Innothera Lab Sa | Gel pour hormonotherapie locale de la secheresse vaginale |
| EP1083880B1 (en) * | 1998-06-03 | 2004-09-01 | Jean-Marc Aiache | Stable gel mixture in the form of a mixture of oleogel and aqueous gel |
| FR2779438B1 (fr) * | 1998-06-03 | 2004-12-24 | Jean Marc Aiache | Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant |
| US6743448B2 (en) * | 2000-12-11 | 2004-06-01 | Abraham H. Kryger | Topical testosterone formulations and associated methods |
| ES2237298B1 (es) * | 2003-07-16 | 2006-11-01 | Italfarmaco, S.A. | Formulaciones mucoadhesivas semisolidas. |
| MX2007009635A (es) * | 2005-02-10 | 2007-09-25 | Orexo Ab | Nuevas composiciones farmaceuticas utiles en la administracion transmucosa de farmacos. |
| DE102005037844A1 (de) * | 2005-08-04 | 2007-04-05 | Intendis Gmbh | Wasserfreies Mehr-Phasen-Gel-System |
| GB2445539A (en) * | 2006-12-29 | 2008-07-16 | Ardana Bioscience Ltd | Bigel composition |
| US8475774B2 (en) * | 2010-02-08 | 2013-07-02 | Johnson & Johnson Consumer Companies, Inc. | Sunscreen compositions comprising an ultraviolet radiation-absorbing polymer |
| WO2012019991A1 (en) * | 2010-08-09 | 2012-02-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of hiv-1 infections |
| MX395212B (es) * | 2011-05-15 | 2025-03-21 | Acerus Biopharma Inc | Geles nasales de liberación controlada de testosterona, métodos y sistemas aplicadores multidosis pre cargados para administración pernasal. |
| US11154535B2 (en) * | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
| WO2014026707A1 (en) * | 2012-08-13 | 2014-02-20 | Edko Pazarlama Tanitim Ticaret Limited Sirketi | Anti-vaginitis compositions with improved release and adherence |
-
2017
- 2017-01-06 ES ES17736445T patent/ES2949053T3/es active Active
- 2017-01-06 US US15/400,517 patent/US20170196896A1/en not_active Abandoned
- 2017-01-06 AU AU2017206048A patent/AU2017206048B2/en active Active
- 2017-01-06 MX MX2018008467A patent/MX393613B/es unknown
- 2017-01-06 EP EP17736445.2A patent/EP3399963B1/en active Active
- 2017-01-06 IL IL300437A patent/IL300437A/en unknown
- 2017-01-06 CN CN201780015750.8A patent/CN108712901A/zh active Pending
- 2017-01-06 GB GB1700220.5A patent/GB2551598B/en active Active
- 2017-01-06 KR KR1020187022738A patent/KR20180117103A/ko active Pending
- 2017-01-06 WO PCT/US2017/012564 patent/WO2017120492A1/en not_active Ceased
- 2017-01-06 JP JP2018554642A patent/JP7055754B2/ja active Active
- 2017-01-06 EP EP22179555.2A patent/EP4091601A1/en active Pending
- 2017-01-06 CA CA3010829A patent/CA3010829A1/en active Pending
-
2018
- 2018-07-06 MX MX2022008277A patent/MX2022008277A/es unknown
- 2018-07-08 IL IL260462A patent/IL260462B2/en unknown
-
2021
- 2021-05-18 US US17/323,496 patent/US20210338693A1/en active Pending
-
2022
- 2022-04-06 JP JP2022063361A patent/JP2022088646A/ja active Pending
-
2023
- 2023-03-20 AU AU2023201712A patent/AU2023201712B2/en active Active
-
2024
- 2024-04-08 JP JP2024062228A patent/JP2024083507A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10888516B2 (en) | Soluble estradiol capsule for vaginal insertion | |
| AU2019204653B2 (en) | Soluble Estradiol Capsule For Vaginal Insertion | |
| CA2451725C (en) | Therapeutic combinations for the treatment of hormone deficiencies | |
| ES2685313T3 (es) | Composiciones farmacéuticas transdérmicas que comprenden agentes activos | |
| US20150359737A1 (en) | Soluble estradiol capsule for vaginal insertion | |
| IL300437A (en) | Gel preparations for administering a drug through the skin to maximize drug concentrations in the rough layer and serum and methods of using them | |
| US20110195114A1 (en) | Transdermal delivery systems for active agents | |
| US20120058981A1 (en) | Androgen pharmaceutical composition and method for treating depression | |
| US20110306582A1 (en) | Androgen pharmaceutical composition and method for treating depression | |
| US20080085877A1 (en) | Therapeutic methods of using estrogen compositions | |
| CA2948287A1 (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| AU2003228314A1 (en) | Androgen pharmaceutical composition and method for treating depression | |
| US20260124136A1 (en) | Soluble estradiol capsule for vaginal insertion | |
| KR102163369B1 (ko) | 질 삽입용 가용성 에스트라디올 캡슐 | |
| WO2008018872A1 (en) | Therapeutic methods of using estrogen compositions |